Cognitive Decline, Cerebral-Spleen Tryptophan Metabolism, Oxidative Stress, Cytokine Production, and Regulation of the Txnip Gene in a Triple Transgenic Mouse Model of Alzheimer Disease

Am J Pathol. 2019 Jul;189(7):1435-1450. doi: 10.1016/j.ajpath.2019.03.006. Epub 2019 Apr 10.

Abstract

Pathologic inflammation in response to injury, infection, or oxidative stress is a proposed mechanism relating cognitive decline to dementia. The kynurenine pathway and thioredoxin-interacting protein (TXNIP) activity regulate inflammation and neurotoxicity in Alzheimer disease (AD). We examined cognitive deficits, kynurenine pathway mediators, TXNIP, and oxidative damage in the cerebrum and spleen, including inflammatory cytokine production by stimulated splenocytes, from female triple transgenic (3xTg-AD) mice in early and late stages of disease progression, and characterized tissue-specific epigenetic regulation of Txnip gene expression. We show that cognitive deficits in 7-month-old 3xTg-AD mice are associated with a stable increase in cerebrum and spleen tryptophan metabolites, with a concomitant increase in amyloid β 40 (Aβ40)/Aβ42 and tau/hyperphosphorylated tau pathologies and a coordinated reduction in spleen proinflammatory cytokine production in 17-month-old mice. The enhanced cerebrum TXNIP expression is associated with increased histone acetylation, transcription factor [Aβ42 or CCCTC-binding factor (CTCF)] binding, and Txnip promoter hypomethylation, whereas the attenuated spleen TXNIP expression is associated with increased histone methylation, reduced CTCF binding, and Txnip promoter hypermethylation. These results suggest a causal relationship among epigenomic state, TXNIP expression, cerebral-spleen tryptophan metabolism, inflammatory cytokine production, and cognitive decline; and they provide a potential mechanism for Txnip gene regulation in normal and pathologic conditions, suggesting TXNIP levels may be a useful predictive or diagnostic biomarker for Aβ40/Aβ42 targeted AD therapies.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease*
  • Amyloid beta-Peptides / genetics
  • Amyloid beta-Peptides / metabolism
  • Animals
  • CCCTC-Binding Factor / genetics
  • CCCTC-Binding Factor / metabolism
  • Carrier Proteins / genetics
  • Carrier Proteins / metabolism
  • Cerebrum* / metabolism
  • Cerebrum* / pathology
  • Cognitive Dysfunction* / genetics
  • Cognitive Dysfunction* / metabolism
  • Cognitive Dysfunction* / pathology
  • Cytokines / genetics
  • Cytokines / metabolism
  • Disease Models, Animal
  • Humans
  • Mice
  • Mice, Transgenic
  • Oxidative Stress*
  • Peptide Fragments / genetics
  • Peptide Fragments / metabolism
  • Spleen* / metabolism
  • Spleen* / pathology
  • Thioredoxins / genetics
  • Thioredoxins / metabolism
  • Tryptophan* / genetics
  • Tryptophan* / metabolism

Substances

  • Amyloid beta-Peptides
  • CCCTC-Binding Factor
  • CTCF protein, human
  • Carrier Proteins
  • Ctcf protein, mouse
  • Cytokines
  • Peptide Fragments
  • TXNIP protein, human
  • Txnip protein, mouse
  • amyloid beta-protein (1-40)
  • amyloid beta-protein (1-42)
  • Thioredoxins
  • Tryptophan